JFS Wealth Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

JFS Wealth Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$7K	–	456
2018 Q3	$7K	Buy	+1,000	New	+$5.61K	﹤0.01%	431

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JFS Wealth Advisors's AUPH Position: Q4 2018 in Review

JFS Wealth Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2018, closing a stake of 1,000 shares — an estimated $7K sold.

JFS Wealth Advisors first reported a position in AUPH in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 61 funds tracked by Wall St. Rank hold AUPH as of Q4 2018.

JFS Wealth Advisors reported no remaining Aurinia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
JFS Wealth Advisors sold 1,000 Aurinia Pharmaceuticals shares in Q4 2018, an estimated $7K.
JFS Wealth Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2018 and held it in 1 quarter.
JFS Wealth Advisors's Aurinia Pharmaceuticals position peaked at $7K in Q3 2018.
61 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2018.

Based on JFS Wealth Advisors's 13F filing for Q4 2018, filed 28 Jan 2019.